Skip to content
Screener

Dianthus Therapeutics DNTH Other income, net (Note 6)

Other income, net (Note 6) at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$331M-209%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1K-100%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$98K+45.9%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$1K+50.0%
TG Therapeutics logo
TG TherapeuticsTGTX
$5.13M+83.7%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Interest and investment income6,2653,791
Loss on investment in former related party(302)(5)
Loss on currency exchange, net(15)(22)
Other expense(249)(98)
Total other income5,6993,666
Net loss$(40,834)$(29,511)
Net loss per share attributable to common stockholders, basic and diluted$(0.85)$(0.82)
Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted48,032,74235,790,700

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's other income, net (note 6)?
Dianthus Therapeutics (DNTH) reported other income, net (note 6) of -$249K in Q1 2026.
How has Dianthus Therapeutics's other income, net (note 6) changed year-over-year?
Dianthus Therapeutics's other income, net (note 6) decreased by 154.1% year-over-year, from -$98K to -$249K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Dianthus Therapeutics's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude